Target Discovery and Characterization
Our long-term objective is to identify pathological pathways, which can be leveraged for the treatment of metabolic disorders including obesity, diabetes, nonalcoholic fatty liver disease (NAFLD) and cardiovascular disorders.
What We Do
We combine innovative discovery platforms with state-of-the-art technologies to uncover novel maladaptive pathways that promote metabolic disorders. We elucidate the molecular mechanism and feasibility as drug target by applying a wide array of investigative approaches including but not limited to clinical samples, transgenic mouse models, indirect calorimetry, molecular biology, lipid and glucose biochemistry as well as small molecule inhibitors.
Our Team
Ersoy Lab is comprised of biomedical research enthusiasts with an interdisciplinary approach and welcomes diversity and inclusion.